Exportin-1 protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Exportin-1 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in Exportin-1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Exportin-1 protein inhibitors: Overview
Exportin 1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), is a eukaryotic protein that mediates the nuclear export of various proteins and RNAs. Exportin-1 recognizes certain RNAs, including viral mRNAs, cellular mRNAs, and small nuclear RNAs (snRNAs), and exports them from the nucleus to the cytoplasm. Exportin 1 affinity for cargo proteins is regulated by binding of Ran-GTP in the nucleus, and Ran-GAP-mediated Ran-GTP hydrolysis releases the cargo proteins in the cytoplasm. Exportin 1 cargo proteins also include tumor suppressor proteins (TSPs), apoptosis inducers and cell cycle regulators. Various haematologic malignancies and solid tumors have been discovered to be dependent on Exportin 1-mediated nuclear export for their survival. Because of this property, exportin 1 is being exploited as an oncology drug target.
Report Highlights
This segment of the Exportin-1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Exportin-1 protein inhibitors Emerging Drugs
Further product details are provided in the report……..
Exportin-1 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Exportin-1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Exportin-1 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Exportin-1 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exportin-1 protein inhibitors drugs.
Exportin-1 protein inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Exportin-1 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in Exportin-1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Exportin-1 protein inhibitors: Overview
Exportin 1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), is a eukaryotic protein that mediates the nuclear export of various proteins and RNAs. Exportin-1 recognizes certain RNAs, including viral mRNAs, cellular mRNAs, and small nuclear RNAs (snRNAs), and exports them from the nucleus to the cytoplasm. Exportin 1 affinity for cargo proteins is regulated by binding of Ran-GTP in the nucleus, and Ran-GAP-mediated Ran-GTP hydrolysis releases the cargo proteins in the cytoplasm. Exportin 1 cargo proteins also include tumor suppressor proteins (TSPs), apoptosis inducers and cell cycle regulators. Various haematologic malignancies and solid tumors have been discovered to be dependent on Exportin 1-mediated nuclear export for their survival. Because of this property, exportin 1 is being exploited as an oncology drug target.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Exportin-1 protein inhibitors R&D. The therapies under development are focused on novel approaches for Exportin-1 protein inhibitors.
This segment of the Exportin-1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Exportin-1 protein inhibitors Emerging Drugs
- Selinexor: Karyopharm Therapeutics
- Felezonexor: Stemline Therapeutics
Further product details are provided in the report……..
Exportin-1 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Exportin-1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Exportin-1 protein inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Exportin-1 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Exportin-1 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exportin-1 protein inhibitors drugs.
Exportin-1 protein inhibitors Report Insights
- Exportin-1 protein inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Exportin-1 protein inhibitors drugs?
- How many Exportin-1 protein inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Exportin-1 protein inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exportin-1 protein inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Exportin-1 protein inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Karyopharm Therapeutics
- Stemline Therapeutics
- Wigen Biomedicine
- Selinexor
- BIIB 100
- Felezonexor
- WJ 1024
Introduction
Executive Summary
Exportin-1 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Exportin-1 protein inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Exportin-1 protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Exportin-1 protein inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Selinexor: Karyopharm Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Felezonexor: Stemline Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
WJ 1024: Wigen Biomedicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Exportin-1 protein inhibitors Key Companies
Exportin-1 protein inhibitors Key Products
Exportin-1 protein inhibitors- Unmet Needs
Exportin-1 protein inhibitors- Market Drivers and Barriers
Exportin-1 protein inhibitors- Future Perspectives and Conclusion
Exportin-1 protein inhibitors Analyst Views
Exportin-1 protein inhibitors Key Companies
Appendix
Executive Summary
Exportin-1 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Exportin-1 protein inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Exportin-1 protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Exportin-1 protein inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Selinexor: Karyopharm Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Felezonexor: Stemline Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
WJ 1024: Wigen Biomedicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Exportin-1 protein inhibitors Key Companies
Exportin-1 protein inhibitors Key Products
Exportin-1 protein inhibitors- Unmet Needs
Exportin-1 protein inhibitors- Market Drivers and Barriers
Exportin-1 protein inhibitors- Future Perspectives and Conclusion
Exportin-1 protein inhibitors Analyst Views
Exportin-1 protein inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Exportin-1 protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Exportin-1 protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Exportin-1 protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Exportin-1 protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products